Background: Opioid dependence is an increasing problem among adolescents and young adults, but in contrast to the standard in the adult population, adoption of pharmacotherapies has been slow. Extended-release naltrexone (XR-NTX) is a promising treatment that has been receiving increasing interest for adult opioid dependence. Clinical chart abstractions were performed on a convenience sample of 16 serial adolescent and young adult cases (mean age 18.5 years) treated for opioid dependence with XR-NTX who attended at least one out-patient clinical follow-up visit.
Case Descriptions: Of these 16 cases, 10 of 16 (63%) were retained in treatment for at least 4 months and nine of 16 (56%) had a 'good' outcome defined as having substantially decreased opioid use, improvement in at least one psychosocial domain and no new problems due to substance use.
Conclusions: These descriptive results suggest that XR-NTX in the treatment of adolescents and young adults with opioid dependence is well tolerated over a period of 4 months and feasible in a community-based treatment setting, and associated with good outcomes in a preliminary, small non-controlled case-series. This probably reflects an overall trend towards greater adoption of medication treatments for this population.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1360-0443.2010.03015.x | DOI Listing |
Addict Sci Clin Pract
January 2025
Center for Technology and Behavioral Health, Geisel School of Medicine, Dartmouth College, Lebanon, NH, 03766, USA.
Background: Opioid-related fatal overdoses are occurring at historically high levels and increasing each year. Accessible social and financial support are imperative to the initiation and success of treatment for Opioid Use Disorder (OUD). Medications for Opioid Use Disorder (MOUD) offer effective treatment but there are many more people with untreated OUD than receiving evidence-based medication.
View Article and Find Full Text PDFPharmacoepidemiol Drug Saf
January 2025
Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, USA.
Purpose: Long-term opioid therapy (LTOT) has been shown to be associated with opioid overdose, but the definition of LTOT varies widely across studies. We use a rigorous LTOT definition to examine risk of opioid overdose by duration of treatment.
Methods: Data were from a large private health insurance provider in North Carolina linked to mortality records from 2006-2018.
Ann Fam Med
January 2025
Department of Family Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Purpose: Offering medication for opioid use disorder (MOUD) in primary care can increase access to effective opioid use disorder treatment and help address the US opioid crisis. We describe a primary care office-based opioid treatment program and addiction consultation service model designed to support small, rural clinics to increase their capacity for MOUD.
Methods: This is an evaluation of an intervention to increase clinic capacity to offer MOUD.
JAMA Netw Open
January 2025
Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.
Importance: Women who use heroin in sub-Saharan Africa face elevated HIV risk linked to structural vulnerability including frequent incarceration. However, little is known about the association between incarceration and drug use and HIV outcomes among women who use heroin in Africa.
Objective: To estimate associations between incarceration and adverse HIV-related and drug use-related outcomes among women who used heroin.
Psychooncology
January 2025
Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, Washington, USA.
Background: Adolescents and young adults (AYA) with cancer experience long-term consequences into survivorship that impact quality of life, including mental health symptoms, substance use, and persistent pain. Given the elevated rates of pain, AYA cancer survivors are at increased risk for opioid pain medication (OPM) exposure, increasing risk for opioid-related negative consequences, particularly for those with mental health symptoms. Minimal research has documented that a considerable proportion of AYAs with cancer receive OPM that continues into survivorship, yet the lack of consensus on the definition of problematic opioid use coupled with the high clinical need for OPM makes it particularly challenging to understand the impact of OPM use in this population.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!